Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function.

Life science alliance - 1 Aug 2024

Bromberger Sophie, Zadorozhna Yuliia, Ressler Julia Maria, Holzner Silvio, Nawrocki Arkadiusz, Zila Nina, Springer Alexander, Røssel Larsen Martin, Schossleitner Klaudia

Abstract excerpt

Targeted therapies against mutant BRAF are effectively used in combination with MEK inhibitors (MEKi) to treat advanced melanoma. However, treatment success is affected by resistance and adverse events (AEs). Approved BRAF inhibitors (BRAFi) show high levels of target promiscuity, which can contribute to these effects. The blood vessel lining is in direct contact with high plasma concentrations of BRAFi, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Endothelium, Vascular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Human Umbilical Vein Endothelial Cells

Share to Imidazoles

Share to MAP Kinase Signaling System

Share to Oximes

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 38839106
DOI: 10.26508/lsa.202402671
PMCID: PMC11153892

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Off-targets of BRAF inhibitors disrupt endothelial signaling and vascular barrier function.PMID 38839106Read ↗

Off-targets of BRAF inhibitors disrupt endothelial signaling and differentially affect vascular barrier functionSemantic proximity Read ↗

Current Insights of BRAF Inhibitors in Cancer.Semantic proximity Read ↗

Biological challenges of BRAF inhibitor therapy.Semantic proximity Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.Semantic proximity Read ↗

B-Raf Inhibition in the Clinic: Present and FutureSemantic proximity Read ↗

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.Semantic proximity Read ↗

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.Semantic proximity Read ↗

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.Semantic proximity Read ↗

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.